Scope, Claims, and US Patent Landscape for US Drug Patent 12,036,219 (Delafloxacin ABSSSI in Overweight/Obese Patients)
What is US 12,036,219 and what does it claim?
US 12,036,219 is directed to a treatment method for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in overweight or obese patients using IV delafloxacin at a fixed regimen.
Core claim concept (independent claim 1)
- Indication: Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Patient population qualifier: overweight or obese
- Drug: delafloxacin or a pharmaceutically acceptable salt/ester/prodrug
- Route: intravenous (IV)
- Dose and regimen: 300 mg twice daily
Dependent BMI narrowing (claims 2-5)
- Claim 2: BMI ≥ 25 (overweight threshold)
- Claim 3: BMI ≥ 30 (obesity threshold)
- Claim 4: BMI ≥ 35 (higher obesity class)
- Claim 5: BMI ≥ 40 (severe obesity class)
Claim chart (scope mapping)
| Claim |
Population qualifier |
Treatment setting |
Drug / regimen |
| 1 |
Overweight or obese (no BMI cut-off stated here) |
IV ABSSSI |
Delafloxacin (or salt/ester/prodrug), 300 mg IV BID |
| 2 |
BMI ≥ 25 |
Same as claim 1 |
Same dosing |
| 3 |
BMI ≥ 30 |
Same as claim 1 |
Same dosing |
| 4 |
BMI ≥ 35 |
Same as claim 1 |
Same dosing |
| 5 |
BMI ≥ 40 |
Same as claim 1 |
Same dosing |
How is the claim scope limited, and what is the practical “at-risk” boundary?
The scope is constrained by three structural elements that must all be met:
- Clinical target: ABSSSI (not generic “bacterial skin infection” or “skin infection”)
- Patient qualifier: overweight/obese, with BMI-specific thresholds only in dependent claims
- Regimen specificity: IV administration and 300 mg twice daily
Regimen specificity drives infringement boundaries
The independent claim is not “delafloxacin for ABSSSI” broadly. It is a method defined by:
- Drug identity: delafloxacin (including salt/ester/prodrug equivalents)
- Dose: 300 mg per administration
- Frequency: twice daily
- Route: IV
Practical interpretation for freedom-to-operate
- IV delafloxacin at 300 mg BID falls within the independent claim if the patient qualifies as overweight/obese and has ABSSSI.
- Changing any one of the following can move coverage outside the literal scope:
- IV to oral (if the product/regimen is oral)
- 300 mg BID to a different dose or different dosing frequency
- delafloxacin to a different quinolone/antibiotic
- ABSSSI to a different infection category
BMI limitations create layered protection
Because dependent claims add BMI thresholds (≥25, ≥30, ≥35, ≥40), the patent does not just cover “overweight or obese” as a concept. It creates stepped coverage by severity:
- A regimen in BMI ≥ 40 patients is covered by claim 5 (and therefore also within the umbrella of claim 1 if claim 1’s “overweight or obese” qualifier is met).
- A regimen in BMI ≥ 25 patients is covered by claim 2.
Composition equivalents are limited to salt/ester/prodrug
Claim 1 uses “delafloxacin or a pharmaceutically acceptable salt, ester, or prodrug thereof.” That is a composition equivalency bridge inside the method claim. It does not extend to other structural analogs or different active ingredients.
What does “overweight or obese” mean in enforceability terms?
Claim 1 uses the phrase “overweight or obese patient.” Claim 2 then anchors a BMI threshold at ≥25, which is the conventional overweight cutoff in standard BMI categorization.
From a claim-construction perspective, the enforceability leverage comes from how BMI floors are pleaded as dependent claim boundaries:
- BMI ≥ 25 is explicitly claimed (claim 2).
- BMI ≥ 30, ≥35, and ≥40 are explicitly claimed (claims 3-5).
This structure indicates that the patent is engineered to cover at least the standard BMI disease-severity bands, with the higher BMI tiers providing fallback claim coverage if a challenger attacks the meaning of “overweight or obese” as used in claim 1.
What is the effective claim scope for competitors and generics?
The claim is a method of treatment claim tied to:
- delafloxacin as active ingredient (including specified derivative categories)
- ABSSSI
- overweight/obese BMI bands
- IV administration
- 300 mg BID dosing
That makes the patent most relevant in scenarios where another party:
- markets a delafloxacin generic or alternative salt/prodrug
- uses the same dosing regimen (300 mg BID IV)
- targets ABSSSI
- treats patients in BMI bands that meet the claim qualifiers
High-risk activity categories
| Activity |
Likely risk under these claims |
| Delafloxacin IV at 300 mg BID for ABSSSI in BMI ≥ 30 patients |
High |
| Delafloxacin IV at 300 mg BID for ABSSSI in BMI ≥ 40 patients |
Highest (claims 4 and 5) |
| Delafloxacin IV but different dose or frequency |
Reduced literal risk |
| Non-IV route (oral formulation) |
Reduced literal risk |
| Different indication (non-ABSSSI) |
Reduced literal risk |
“Design-around” options inside the claim language
Since the claim is narrowly defined by regimen parameters, typical design-around vectors include:
- Dose change: use a regimen not equal to 300 mg BID
- Dosing frequency change: once daily or other frequency
- Route change: non-IV administration
- Indication framing: avoid ABSSSI-labeled treatment in the relevant marketing or prescribing instructions
- Avoiding BMI qualifiers: practically hard to control in real-world prescribing, but claim scope is tiered by BMI thresholds, with the tightest coverage at higher BMI.
How does this patent fit into the broader US delafloxacin ABSSSI landscape?
US method patents for antibiotics commonly split into two strategic layers:
- Core antibiotic ABSSSI claims (drug + indication + regimen)
- Patient subgroup claims (e.g., BMI, renal function, pathogen subsets) to extend exclusivity or secure additional coverage windows even when core regimen claims face validity risk
This patent’s claim architecture is consistent with that second layer:
- It does not expand to new infection types.
- It does not change the drug class beyond delafloxacin.
- It narrows and protects by BMI-defined subpopulations while keeping the ABSSSI and IV 300 mg BID regimen constant.
Landscape map (functional view)
| Layer |
Typical claim drivers |
What US 12,036,219 adds |
| Indication/regimen |
ABSSSI + dosing |
Keeps ABSSSI + IV 300 mg BID fixed |
| Patient stratification |
BMI, comorbidities, demographics |
Adds overweight/obese and BMI cut-offs (25/30/35/40) |
What claim elements are likely to matter most in validity challenges (litigation posture)?
Even without inspecting the full specification and prosecution history, the claim language itself flags typical pressure points:
- Patient subgroup novelty and support
- BMI thresholds (≥25, ≥30, ≥35, ≥40) raise questions about whether the patent has adequate support for those cut-offs in the specification and whether they are tied to demonstrated treatment effect differences or dosing adjustments.
- Definiteness of clinical categorization
- ABSSSI must be consistently defined in clinical practice. If the patent relies on definitions that are not clearly anchored, that can become an interpretation issue.
- Regimen obviousness
- A method claim that uses a previously known dosing regimen (here, 300 mg IV BID) with only patient stratification can face an obviousness attack if the stratification would be considered routine.
These are not conclusions about validity; they identify the elements that would typically drive litigation focus because they are the only “moving parts” in this claim set: ABSSSI, BMI subgrouping, and IV 300 mg BID.
How strong is coverage at different BMI levels?
The claim set is stratified to preserve coverage across BMI severity bands:
- BMI ≥ 25: protected under claim 2
- BMI ≥ 30: protected under claim 3
- BMI ≥ 35: protected under claim 4
- BMI ≥ 40: protected under claim 5
Since claim 1 covers “overweight or obese” without specifying BMI, claim 1 provides the broadest patient coverage, while claims 2-5 act as narrower fallbacks tied to exact BMI thresholds.
Coverage ladder (who fits where)
| Patient BMI |
Claim coverage pathway |
| 25 to 29.9 |
claim 1 + claim 2 (BMI ≥ 25) |
| 30 to 34.9 |
claim 1 + claim 3 (BMI ≥ 30) |
| 35 to 39.9 |
claim 1 + claim 4 (BMI ≥ 35) |
| ≥ 40 |
claim 1 + claim 5 (BMI ≥ 40) |
Patent landscape: what matters for investors and R&D strategists
From a business perspective, this patent is a value amplifier rather than a foundational right:
- It does not create new drug-device technology.
- It does not expand to new antibiotic mechanisms.
- It monetizes a narrow but prescribable segment: ABSSSI treated with delafloxacin IV 300 mg BID in overweight/obese patients.
Implications for:
- Generic delafloxacin entrants: risk concentrates around label-concordant ABSSSI dosing and real-world prescribing in BMI bands.
- Brand marketers: enforcement leverage increases if clinical pathways or formularies emphasize BMI-specific dosing concerns.
- R&D teams: if developing alternative regimens or oral formulations, the regimen and route are the primary design-around levers.
Most actionable “landscape” takeaway
The only patentable-looking differentiator in this claim set is the BMI-defined patient subgroup applied to a fixed, specific regimen (IV 300 mg BID). That means:
- value depends on how often ABSSSI is treated using that exact dosing and on whether patient BMI is part of the prescribing/clinical decision workflow.
- infringement exposure is highest when labeling, clinical guidance, and real-world care align tightly with the claim language.
Key Takeaways
- US 12,036,219 claims a method of treating ABSSSI in overweight/obese patients using delafloxacin IV 300 mg twice daily.
- Claims 2-5 lock in BMI cut-offs at ≥25, ≥30, ≥35, and ≥40, creating a stepped protection ladder by obesity severity.
- The practical “at-risk” boundary is driven by three fixed elements: ABSSSI indication, IV 300 mg BID regimen, and delafloxacin active ingredient.
- For competitors, the main design-around levers inside the claim text are route (non-IV), dose/frequency (not 300 mg BID), and indication framing (not ABSSSI).
FAQs
-
Does US 12,036,219 cover non-IV delafloxacin regimens?
No. The method claim specifies intravenous (IV) administration.
-
What delafloxacin dosing is required for claim coverage?
300 mg twice daily.
-
Is BMI explicitly required in the independent claim?
Claim 1 uses “overweight or obese” without a numeric BMI threshold, while BMI thresholds appear in dependent claims (≥25, ≥30, ≥35, ≥40).
-
Which claim covers patients with BMI ≥ 40?
Claim 5 (BMI ≥ 40).
-
Is the claim limited to ABSSSI and not other skin infections?
Yes. The method is for Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
References
[1] User-provided claim text for US Drug Patent 12,036,219 (claims 1-5).
